Hemodynamic and functional assessment of patients with sickle cell disease and pulmonary hypertension. - Wikidata - awgldk - TriplyDB

Hemodynamic and functional assessment of patients with sickle cell disease and pulmonary hypertension.

Hemodynamic and functional assessment of patients with sickle cell disease and pulmonary hypertension.

http://www.wikidata.org/entity/Q36330543

about

Group 5 Pulmonary Hypertension: The Orphan's Orphan Disease.The role of fibrocytes in sickle cell lung disease.Pulmonary complications of sickle cell disease.Proteomic identification of altered apolipoprotein patterns in pulmonary hypertension and vasculopathy of sickle cell disease Pulmonary hypertension in Nigerian adults with sickle cell anemia.Physical activity level and performance in the six-minute walk test of children and adolescents with sickle cell anemia.Segmentation and quantification of pulmonary artery for noninvasive CT assessment of sickle cell secondary pulmonary hypertension.Reconstructing sickle cell disease: a data-based analysis of the "hyperhemolysis paradigm" for pulmonary hypertension from the perspective of evidence-based medicine.Computed tomography correlates with cardiopulmonary hemodynamics in pulmonary hypertension in adults with sickle cell disease.Cellular, pharmacological, and biophysical evaluation of explanted lungs from a patient with sickle cell disease and severe pulmonary arterial hypertension Pulmonary function in children and adolescents with sickle cell disease: have we paid proper attention to this problem?Risk factors for death in 632 patients with sickle cell disease in the United States and United Kingdom Pulmonary hypertension in hemolytic disorders: pulmonary vascular disease: the global perspective.Exercise capacity and haemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan: results of the ASSET studies.Lung function and six-minute walk test performance in individuals with sickle cell disease.Elevated tricuspid regurgitation velocity and decline in exercise capacity over 22 months of follow up in children and adolescents with sickle cell anemia.Vasculopathy in sickle cell disease: Biology, pathophysiology, genetics, translational medicine, and new research directions Hematological and hemorheological determinants of the six-minute walk test performance in children with sickle cell anemia.The PhysioFlow thoracic impedancemeter is not valid for the measurements of cardiac hemodynamic parameters in chronic anemic patients Vasculopathy and pulmonary hypertension in sickle cell disease.Sickle cell disease and venous thromboembolism: what the anticoagulation expert needs to know Uric Acid as a potential biomarker of pulmonary arterial hypertension in patients with sickle cell disease.Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity.Echocardiographic markers of elevated pulmonary pressure and left ventricular diastolic dysfunction are associated with exercise intolerance in adults and adolescents with homozygous sickle cell anemia in the United States and United Kingdom.Risk factors and mortality associated with an elevated tricuspid regurgitant jet velocity measured by Doppler-echocardiography in thalassemia: a Thalassemia Clinical Research Network report Abnormalities in cardiac structure and function in adults with sickle cell disease are not associated with pulmonary hypertension.NT-pro brain natriuretic peptide levels and the risk of death in the cooperative study of sickle cell disease.Increased pulmonary pressures and myocardial wall stress in children with severe malaria Reduced fitness and abnormal cardiopulmonary responses to maximal exercise testing in children and young adults with sickle cell anemia.Nitric oxide and arginine dysregulation: a novel pathway to pulmonary hypertension in hemolytic disorders A novel expression of exercise induced pulmonary hypertension in human immunodeficiency virus patients: a pilot study.Relative systemic hypertension in patients with sickle cell disease is associated with risk of pulmonary hypertension and renal insufficiency A novel molecular signature for elevated tricuspid regurgitation velocity in sickle cell disease.Infrared imaging of nitric oxide-mediated blood flow in human sickle cell disease.Pathophysiology and treatment of pulmonary hypertension in sickle cell disease Paradoxical protection from atherosclerosis and thrombosis in a mouse model of sickle cell disease.Allogeneic hematopoietic stem-cell transplantation for sickle cell disease.Reduced sensitivity of the ferroportin Q248H mutant to physiological concentrations of hepcidin Clinical correlates of acute pulmonary events in children and adolescents with sickle cell disease Hemodynamic predictors of mortality in adults with sickle cell disease

P2860

Q30248872-A962F2A6-7271-4246-AFBE-F39EB6723151 Q30427773-F139B1FA-962C-456D-B040-FB5C0FFF63F2 Q30515769-5701082B-D270-447F-A95B-A9FC14780CE5 Q33385956-79FE10C3-49EC-4EBF-8354-398B80BC6FC0 Q33674097-9F40713C-AF50-42B8-83C7-F7A3970C1281 Q33759029-34F027C2-00F7-4C36-BB5F-5BE517122E2A Q33766843-C5BEC7A9-D4AB-418E-BDF6-71883986608A Q33803027-70DC6B56-0944-4618-8284-08B55959F698 Q33805998-6DBA96F5-2FDB-4E3F-A4B8-B079EB12C33C Q33806253-B150D8A1-F1BE-4CF7-BD40-6E2303759EBF Q33809216-EFE50F1B-8426-418E-B39C-6580FF0C1D77 Q33837174-E3F5129D-8B34-4ED5-A7DE-600060AEFBD9 Q33899415-58C70F0F-FCAF-4189-94E6-4A3EC34B4633 Q34038886-729E89DD-1187-4CEC-AFDC-9BBD6D38C219 Q34280652-A26E8FD6-D989-4FBB-B2D9-B05221009C69 Q34451512-F15C6E4F-F98E-40E0-A363-E470C15E8918 Q34992760-0446AB54-959F-4F58-8514-2D98AEBCC76C Q35023443-3506933D-5AFB-4512-8EC2-1DA47AE22A9C Q35027985-45D9AB83-A5A9-4DFC-8461-2D08810428B2 Q35086394-1E3E7EF7-5EFF-4E95-8BFE-67D0F2BD8D31 Q35105431-1FAECEEC-3989-4A3B-9469-2392176CE6B1 Q35106381-8CCC5226-E8F2-44AC-85D0-BC9D65565081 Q35140978-2A1B2FED-36F5-4840-A15D-38E70C6A0EB0 Q35243386-E609E4E4-0EFA-4BDF-86BB-211290478DA4 Q35346284-FA267F98-4C9E-4F2F-A14E-343FB5E09EB8 Q35435386-BC550DF5-7B57-4CF5-82FB-3467FF9770BE Q35508045-A5F4161E-4638-412F-A683-21D5F6C70275 Q35508081-AD632FA3-ED56-497B-96BE-A61BC706133C Q35588591-3BA516CF-D5E2-45B8-99A1-77E44E3A8616 Q35590733-F58F2E55-4711-4DF3-84EC-B49835E8A435 Q35920171-B754066C-4473-43AA-B02D-19954FAF7045 Q36100581-99BF8B50-6FD5-4DB7-8304-9C8271EBA7FF Q36238248-956E119C-95D3-41C8-B23A-8EAC59D3A061 Q36354572-3D0D1A80-9587-41A4-9DE6-100D531793D1 Q36596861-749FF0EF-9E67-4735-81A7-F31372FE06E6 Q36657988-F6693137-1C51-4D83-84DC-B379AEF2C813 Q36769277-E6DA1CEA-3F02-4B8B-80A2-F90025537F2A Q36862359-9E85524E-FC43-4405-B5B3-9DACCC5ECDB0 Q36947395-09456353-D685-4917-A84C-76839106C325 Q36999803-A91C80EB-D67B-4D20-8250-59BAB7ED844E

P2860

Hemodynamic and functional assessment of patients with sickle cell disease and pulmonary hypertension.

http://www.wikidata.org/entity/Q36330543

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

2007年學術文章

@zh

2007年學術文章

@zh-hant

name

Hemodynamic and functional ass ...... se and pulmonary hypertension.

@ast

Hemodynamic and functional ass ...... se and pulmonary hypertension.

@en

type

label

Hemodynamic and functional ass ...... se and pulmonary hypertension.

@ast

Hemodynamic and functional ass ...... se and pulmonary hypertension.

@en

prefLabel

Hemodynamic and functional ass ...... se and pulmonary hypertension.

@ast

Hemodynamic and functional ass ...... se and pulmonary hypertension.

@en

P1433

Q36330543-69BE7CD4-FD60-49AF-93F3-D317D763BE70

P1476

Q36330543-3A250448-3936-4803-BA7D-23B17E9581F3

P2093

Q36330543-2BE4A924-4AAC-4274-9066-F02944DDE618

Q36330543-306EE89F-262E-4052-A129-53ADA2FFF21C

Q36330543-3A42C1A3-8B20-40D8-88DA-98812969375F

Q36330543-655DCD06-84AE-4592-9935-9EE44F8B7937

Q36330543-9ADB4A91-4D08-463E-A988-C30A403B0AAE

Q36330543-AB3E30DD-50FE-4A21-8336-A109A5D2BE19

Q36330543-AE77D304-D1EF-4B8C-AFF1-5CD6AEE1A259

Q36330543-B5093FBC-C9C6-4D4C-8840-C1DF133D084E

Q36330543-C3FFA7F6-B299-4BEC-A4CD-3B9874D0CB37

Q36330543-E9B69218-A8EC-45B1-9FD4-477745F23428

P2860

Q36330543-0B685982-8214-4D6A-BB86-25EBB22EC820

Q36330543-2B7596C4-DFFF-456D-972A-3776DEF62E4D

Q36330543-2D81DBC8-C357-493F-9773-FA514B1AE020

Q36330543-31A663C6-387B-439C-8803-41A11345A2D5

Q36330543-31E7D79C-2727-4380-B642-FB5B611A3967

Q36330543-3234D6A7-4A21-43DD-9503-1A5A94C02F0C

Q36330543-35E7A2BD-F8DC-4579-93F0-7EF4C2ACFA24

Q36330543-3E5569F7-80FD-4416-BB79-8B9FF19B6672

Q36330543-563D42F0-D37A-4991-992D-C358C23073A1

Q36330543-5C88BF5A-405D-4D91-B84B-5B329ACEEB73

P304

Q36330543-F156F121-10F4-46CD-8A7B-DE8B9D22341B

P31

Q36330543-73E6B9DE-B131-4F7E-8849-4E072C726649

P356

Q36330543-215775E4-31E2-45B2-83D7-828859231655

P407

Q36330543-E2A1BE66-21CF-411D-B9E8-E0F3FB7480BF

P433

Q36330543-465A8E96-5C58-4FF0-90EC-30CCBD77246C

P478

Q36330543-AF2BAF71-B8CD-478B-8AAD-8EE8D3283A72

P50

Q36330543-43DD656D-6BF9-41FA-91D6-247A5FF56C0B

P577

Q36330543-808C777C-51DC-45FA-8367-D23753E78DB6

P698

Q36330543-6D1C067C-C038-4F56-B4EE-1E6C2E28414A

P921

Q36330543-D8C33DEC-329E-4F1C-8CAC-329140948E8C

Q36330543-DFC43167-AA92-4657-9727-95634A9332F1

Q36330543-E5BDD66A-3369-48CA-9921-9FAB7AB50DAB

P932

Q36330543-2D669BF3-EE8B-465E-B980-D5AF7F4D3455

P356

RCCM.200610-1498OC

P1433

American Journal of Respiratory and Critical Care Medicine

P1476

Hemodynamic and functional ass ...... se and pulmonary hypertension.

@en

P2093

Anastasia Anthi

http://www.w3.org/2001/XMLSchema#string

Angelo M Taveira-Dasilva

http://www.w3.org/2001/XMLSchema#string

Christian J Hunter

http://www.w3.org/2001/XMLSchema#string

Clara C Chen

http://www.w3.org/2001/XMLSchema#string

James Nichols

http://www.w3.org/2001/XMLSchema#string

Lewis J Rubin

http://www.w3.org/2001/XMLSchema#string

Lori Hunter

http://www.w3.org/2001/XMLSchema#string

Maria L Jison

http://www.w3.org/2001/XMLSchema#string

Nilo A Avila

http://www.w3.org/2001/XMLSchema#string

Roberto F Machado

http://www.w3.org/2001/XMLSchema#string

P2860

Standardization of Spirometry, 1994 Update. American Thoracic Society

ATS statement: guidelines for the six-minute walk test.

Sitaxsentan therapy for pulmonary arterial hypertension.

The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease.

Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease

Pulmonary complications of sickle cell anemia. A need for increased recognition, treatment, and research.

ATS/ACCP Statement on cardiopulmonary exercise testing.

Chronic sickle cell lung disease: new insights into the diagnosis, pathogenesis and treatment of pulmonary hypertension.

Diastolic dysfunction is an independent risk factor for death in patients with sickle cell disease.

The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension.

P304

1272-1279

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1164/RCCM.200610-1498OC

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

175

http://www.w3.org/2001/XMLSchema#string

P50

P577

2007-03-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17379852

http://www.w3.org/2001/XMLSchema#string

P921

sickle-cell disease

arterial hypertension

P932

2176091

http://www.w3.org/2001/XMLSchema#string